Trial Profile
A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 08 Sep 2014 Results reported in Lancet Respiratory Medicine and presented at the 2014 International Congress of the European Respiratory Society (ERS).
- 12 May 2014 According to AstraZeneca media release, results from this trial presented at the American Thoracic Society (ATS) 2014, on 19 May 2014.